| Name | Title | Contact Details |
|---|
Modulim is a pioneer in optical imaging solutions powered by spatial frequency domain imaging (SFDI) for noninvasive tissue and vascular assessment. Powered by SFDI, our Clarifi® Imaging System helps clinicians identify patients at-risk of complications due to microvascular dysfunction. The #ClarifiImagingSystem quantifies and maps five biomarkers of microvascular tissue oxygenation and perfusion. As a result, clinicians can quickly identify at-risk patients for earlier and more timely intervention so they may prevent complications such as diabetic foot ulcers and amputations. With its widespread adoption, our technology solutions have the potential to save limbs and lives, improve outcomes and reduce costs across the continuum of care by enabling early detection and intervention. Clarifi is affordable and easily integrated into a clinician`s practice. Clarifi imaging is supported by reimbursement (Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code (0061U). Our proprietary technology - SFDI - was invented by Modulim`s founder and CTO David Cuccia, Ph.D., and his colleagues at UC Irvine`s Beckman Laser Institute. SFDI is a noninvasive tissue oxygen saturation technology that combines structured illumination with multiple wavelengths of light (visible and near-infrared) to allow for deeper and layer-specific assessment of tissue oxygenation and hemoglobin. This unique technology deciphers the reflection, absorbance, and scattering of light in tissue. Both David and Amaan Mazhar, Ph.D., Modulim`s VP of Research & Development, are both internationally-recognized experts in the field of medical photonics. #seebeyond
InterVene`s mission is to provide the first effective and widely-utilized therapy for patients suffering from the painful and costly symptoms of Chronic Venous Insufficiency (CVI) due to deep vein reflux (DVR).
Prestige Medical is a Northridge, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Pro2 Solutions is a American Canyon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ability to offer peace of mind to patients while benefitting physicians, who may wish to reduce safety concerns, side effects and adverse events for their patients.